Drilldown: Medicines
Medicines > duration 
:
3-5 hours or
6-12 hours or
6–10 h subjective; full pharmacologic effect considerably longer.
:
3-5 hours or
6-12 hours or
6–10 h subjective; full pharmacologic effect considerably longer. Use the filters below to narrow your results.
generic:
brand:
classes:
Designer benzodiazepine (1) ·
Research material (1) ·
Sedative-Hypnotic (1) ·
Triazolobenzodiazepine (1) ·
[[:Category:Antihypertensives|Antihypertensive]] (1) ·
[[:Category:Antisecretory_agents|Gastric acid suppressant]] (1) ·
[[:Category:H2_receptor_antagonists|Histamine H2 receptor antagonist]] (1) ·
[[:Category:Insulins|Insulin]] (2) ·
[[:Category:Mealtime_insulins|Mealtime (bolus) insulin]] (2) ·
[[:Category:Rapid-acting_insulins|Rapid-acting insulin analog]] (2) ·
[[:Category:Thiazide_diuretics|Thiazide diuretic]] (1)
mechanism:
None (1) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
'"`UNIQ--vote-00000138-QINU`"' Decreases urinary calcium (used in stone prevention); raises serum uric acid, glucose, and lipids modestly; non-anion-gap hypokalemic metabolic alkalosis is the characteristic electrolyte pattern'"`UNIQ--ref-00000139-QINU`"'. (1) ·
'"`UNIQ--vote-00000255-QINU`"' Less potent and shorter-acting than PPIs but with faster on-effect; suitable for on-demand acid suppression. Largely renally cleared; dose-adjust in renal impairment to avoid CNS effects (confusion in elderly)'"`UNIQ--ref-00000256-QINU`"'. (1) ·
'"`UNIQ--vote-00000584-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio. Ultra-rapid formulations (Lyumjev) add treprostinil and citrate to accelerate absorption further'"`UNIQ--ref-00000585-QINU`"'. (1)
uses:
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
'"`UNIQ--vote-0000013A-QINU`"', '"`UNIQ--vote-0000013B-QINU`"', '"`UNIQ--vote-0000013C-QINU`"', '"`UNIQ--vote-0000013D-QINU`"' (1) ·
'"`UNIQ--vote-00000257-QINU`"', '"`UNIQ--vote-00000258-QINU`"', '"`UNIQ--vote-00000259-QINU`"', '"`UNIQ--vote-0000025A-QINU`"' (1) ·
'"`UNIQ--vote-00000586-QINU`"', '"`UNIQ--vote-00000587-QINU`"', '"`UNIQ--vote-00000588-QINU`"' (1) ·
'"`UNIQ--vote-000005EF-QINU`"', '"`UNIQ--vote-000005F0-QINU`"', '"`UNIQ--vote-000005F1-QINU`"' (1)
starting dose:
12.5-25 mg PO once daily (1) ·
20 mg PO twice daily, or 40 mg at bedtime (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) ·
SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose (1) ·
SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose. Typical total daily dose 0.5-1 U/kg/d split between basal and prandial coverage in T1DM (1)
preparations:
10 mg, 20 mg, 40 mg tablets; chewables; 40 mg/5 mL oral suspension; 10 mg/mL IV (1) ·
100 U/mL (Humalog, Admelog, Lyumjev) vials, pens, cartridges; 200 U/mL Humalog KwikPen (1) ·
100 U/mL (NovoLog, Fiasp) vials, pens, cartridges (1) ·
12.5 mg capsules; 12.5, 25, 50 mg tablets (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)
fda max:
routes:
onset:
duration: (Click arrow to add another value)
halflife:
2.5-3.5 hours; longer in renal impairment'"`UNIQ--ref-0000025B-QINU`"' (1) ·
6-15 hours'"`UNIQ--ref-0000013E-QINU`"' (1) ·
Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) ·
~1 hour SC'"`UNIQ--ref-00000589-QINU`"' (1) ·
~80 minutes SC'"`UNIQ--ref-000005F2-QINU`"' (1)
bioavailability:
pregnancy:
None (1) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Generally considered safe; widely used. Cleared in lactation at low levels.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; aspart is widely used.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; lispro is widely used.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 5 results in range #1 to #5.